Related by context. All words. (Click for frequent words.) 78 class anticancer quinolone 76 Bortezomib 75 Hsp# Inhibitor 75 CYT# potent vascular disrupting 74 Xanafide 74 nucleoside analog 74 Glufosfamide 74 2 methoxyestradiol 73 generation purine nucleoside 73 Sapacitabine 73 Blinatumomab 73 pan HDAC inhibitor 73 Maribavir 73 proteasome inhibitor 73 Epratuzumab 72 polymerase inhibitor 72 imatinib Gleevec ® 72 Carfilzomib 72 XYOTAX TM 72 orally bioavailable 72 Talabostat 72 Nucleoside 72 liposomal formulation 72 AEG# 72 Meets Primary Endpoint 72 Lenalidomide 72 Albuferon TM 72 alpha folate receptor 72 Dasatinib 72 Tezampanel 72 erlotinib Tarceva ® 72 Pegloticase 71 small molecule Hedgehog 71 vinca alkaloid 71 Ridaforolimus 71 nucleoside analogue 71 PEGylated Fab fragment 71 non nucleoside inhibitor 71 Annamycin 71 Antitumor Activity 71 radiation sensitizer 71 sapacitabine CYC# 71 developing Bicifadine serotonin 71 Seliciclib 71 ara C 71 refractory chronic lymphocytic 71 orally administered inhibitor 71 Perifosine 71 CYC# 71 Omacetaxine 71 PNP inhibitor 71 myelofibrosis polycythemia vera 71 Romidepsin 71 Ceflatonin R 71 sunitinib Sutent ® 71 Phase 2b Clinical Trial 71 IMiDs R 71 evaluating tivozanib 71 Erlotinib 71 Aflibercept 70 Temsirolimus 70 potent topoisomerase II 70 sorafenib tablets 70 Irinotecan 70 alkylating agent 70 selective antagonist 70 dasatinib Sprycel ® 70 Xeloda ® 70 Traficet EN 70 GW# [003] 70 sodium glucose cotransporter 70 selective modulator 70 YONDELIS 70 allosteric modulator NAM 70 Elvitegravir 70 both intercalates DNA 70 Previously Treated 70 Panzem R 70 vascular disrupting agent 70 Tanespimycin 70 RNAi Therapeutic 70 Cutaneous T 70 Anthracycline 70 Phase 2a Clinical Trial 70 MEK Inhibitor 70 Pharmacokinetics PK 70 Fludarabine 70 novel topoisomerase 70 targeted radiotherapeutic 70 protein tyrosine phosphatase 1B 70 Oral Fingolimod 70 Ofatumumab 70 HDAC Inhibitor 70 Safinamide 70 Panzem R NCD 70 mGluR5 negative 70 Vicriviroc 70 TNF Tumor Necrosis Factor 70 cetuximab Erbitux R 70 docetaxel Taxotere ® 70 Archexin 70 polymerase inhibitors 70 Pathway Inhibitor 70 Personalized Immunotherapy 70 unique alkylating agent 70 Bevacizumab 70 generation Hsp# inhibitor 70 Cloretazine 69 essential thrombocythemia ET 69 Thiarabine 69 #ME# 69 Aplidin R 69 PKC# 69 Anti Tumor Activity 69 mTOR inhibitor 69 Nilotinib 69 HCV protease 69 metaglidasen 69 nucleoside reverse transcriptase inhibitor 69 Eculizumab 69 receptor tyrosine kinase inhibitor 69 Trastuzumab 69 Well Tolerated 69 oral proteasome inhibitor 69 Novel Oral 69 Pralatrexate 69 Drug Candidate 69 Alfacell proprietary ribonuclease 69 selectively inhibits 69 Randomized Phase 69 Relapsed Refractory 69 Gemzar ® 69 IAP inhibitor 69 signal transduction inhibitor 69 Aurora Kinase 69 MAGE A3 ASCI 69 JAK2 Inhibitor 69 novel immunomodulatory 69 PEGylated anti 69 oral prodrug 69 bortezomib Velcade R 69 Zorbtive TM 69 thalidomide Thalomid 69 GSK '# 69 histone deacetylase HDAC inhibitor 69 Doxorubicin 69 Clevudine 69 Daclizumab 69 Amrubicin 69 Cloretazine VNP#M 69 humanized anti 69 seliciclib CYC# 69 Deforolimus 69 LymphoStat B belimumab 69 PEG SN# 69 mGluR5 NAM 69 Darinaparsin 69 Antiangiogenic 69 Ixabepilone 69 Diffuse Large B 69 Tesetaxel 69 investigational oral inhibitor 69 Ibritumomab Tiuxetan 69 Dapagliflozin 69 Elotuzumab 69 Peginterferon alfa 2b 69 Clofarabine 69 Methylnaltrexone 69 CDK inhibitor 69 Pivotal Phase 69 Ceftaroline 69 relapsed MM 69 5 FU leucovorin 69 Aliskiren 69 Nexavar ® 69 Phase 2b Trial 69 Phase IIb Trial 69 Bavituximab 69 Linaclotide 69 Bafetinib 69 Eltrombopag 69 Alemtuzumab 69 SPRYCEL ® 69 Myelofibrosis 69 tigecycline 68 HGS ETR2 68 luteinizing hormone releasing 68 IMiDs ® 68 TAFA# 68 IMiDs ® compound 68 MKC# MKC# PP 68 XL# XL# 68 Tumor Necrosis Factor 68 Phase IIb Clinical Trial 68 MGd 68 vinca alkaloids 68 CCX# B 68 peripherally acting 68 Lubiprostone 68 Preclinical Data 68 Monotherapy 68 oral dihydropyrimidine dehydrogenase DPD 68 Denufosol 68 Combination REOLYSIN R 68 novel VDA molecule 68 MEK inhibitor 68 BAY #-# 68 pharmacokinetic interactions 68 Elesclomol 68 Iloperidone 68 Marqibo TM 68 cell lymphoma CTCL 68 alvespimycin 68 Camptosar ® irinotecan 68 Capecitabine 68 Golimumab 68 Belimumab 68 tumor vascular disrupting 68 EZN 68 PDE4 inhibitor 68 FOLOTYN ® 68 Phase #b/#a clinical 68 small molecule chemotherapeutic 68 HER2 positive metastatic breast 68 Cannabinor 68 selective serotonin 2C receptor 68 HGS ETR1 68 Prolongs Survival 68 Kinase Inhibitor 68 familial amyloidotic polyneuropathy FAP 68 hormone LHRH antagonist 68 Epidermal Growth Factor Receptor 68 oral isoform selective HDAC 68 advanced metastatic renal 68 HSP# inhibitor 68 paclitaxel Taxol ® 68 mapatumumab 68 IAP inhibitors 68 pralatrexate injection folate analogue 68 vapreotide acetate 68 highly selective inhibitor 68 Decitabine 68 Elagolix 68 Fulvestrant 68 fosbretabulin 68 Tamibarotene 68 Gleevec resistant 68 selective inverse agonist 68 NS5B polymerase 68 sorafenib Nexavar 68 Nitazoxanide 68 chronic eosinophilic leukemia 68 docetaxel Taxotere R 68 Cloretazine ® 68 Pivotal Phase III 68 Medidur ™ FA 68 evaluating picoplatin 68 immunotherapeutic agent 68 Orally Active 68 intravesical infusion therapy 68 PI3K/Akt pathway inhibitor 68 Anti Tumor 68 virus HCV protease inhibitor 68 Vidaza ® 68 MGCD# [001] 68 irinotecan doxorubicin oxaliplatin paclitaxel 68 novel emulsion formulation 68 Pertuzumab 68 leukemia CLL 68 targeting CD# 68 Brentuximab Vedotin SGN 68 Enzyme Replacement Therapy 68 bevacizumab Avastin R 68 PSMA ADC 68 Teriflunomide 68 Ecallantide 68 INCB# [001] 68 cutaneous T 68 Hormone Refractory Prostate Cancer 68 D aspartate NMDA receptor 68 relapsed multiple myeloma 68 gemcitabine Gemzar ® 68 Milatuzumab 68 OMP #M# 68 nilotinib Tasigna ® 68 Renal Cell Carcinoma 68 sorafenib Nexavar ® 68 Pemetrexed 68 alfa 2a 68 Vidofludimus 68 Metastatic Melanoma 68 chimeric monoclonal antibody 68 inhibits topoisomerase II 68 Tarvacin 68 Romiplostim 67 Tyrima 67 Protease Inhibitor 67 Alocrest 67 Uricase PEG 67 topoisomerase II inhibitor 67 Vidaza azacitidine 67 CYP#A# CYP#D# 67 Chemokine Receptor 67 selective inhibition 67 RhuDex ® 67 Orally administered 67 TKB# 67 triphendiol 67 Talactoferrin 67 apoptosis inducer 67 sunitinib malate 67 systemic anaplastic large 67 Advanced Renal Cell 67 microtubule inhibitor 67 relapsed leukemia 67 Granulocyte Colony Stimulating Factor 67 AAG geldanamycin analog 67 small molecule thrombopoietin 67 CEQ# 67 5 HT6 receptor 67 selective orally bioavailable 67 AKT inhibitor 67 lenalidomide Revlimid R 67 Completes Patient Enrollment 67 CTAP# Capsules 67 potent antiproliferative 67 Palifosfamide 67 cisplatin gemcitabine 67 oral isotype selective HDAC 67 Investigational Drug 67 Apaziquone 67 Pafuramidine 67 ALN TTR 67 Ozarelix 67 investigational monoclonal antibody 67 pan histone deacetylase 67 DOXIL 67 paclitaxel Taxol 67 panobinostat 67 Investigational Treatment 67 Guanilib 67 Bendamustine 67 Leukemias 67 somatostatin analogue 67 MEK inhibitors 67 Humanized Anti 67 ceftazidime 67 Pegylated 67 TELINTRA 67 Hedgehog Pathway Inhibitor 67 dopamine D2 67 dasatinib Sprycel 67 XL# anticancer compounds 67 Initiate Phase 67 leukemia AML 67 Metastatic Colorectal Cancer 67 adalimumab Humira 67 Investigational Compound 67 bevacizumab Avastin ® 67 refractory NSCLC 67 Presents Preclinical Data 67 delta opioid receptor 67 vascular disrupting agents 67 Philadelphia Chromosome Positive 67 anticancer compound 67 accumulate preferentially 67 forodesine 67 Bezielle 67 LHRH antagonist 67 trastuzumab Herceptin R 67 Luteinizing Hormone Releasing Hormone 67 nucleoside analogues 67 Tyrosine Kinase Inhibitor 67 vidofludimus 67 Trabectedin 67 FUSILEV enhances 67 Aplidin 67 mitogen activated ERK kinase 67 Patients Treated With 67 Clinical Trial Results 67 generation nucleoside analog 67 carcinoid syndrome 67 sapropterin dihydrochloride 67 selective kinase inhibitor 67 IMA# 67 Refractory Hodgkin Lymphoma 67 AQD class 67 protein kinase inhibitor 67 NMDA antagonist 67 peptidic compound 67 telomerase therapeutic 67 Gastrointestinal Stromal Tumors 67 Presents Positive 67 Thiovir 67 INSPIRE Trial Phase III 67 pharmacologically active isomer 67 pathophysiological effects 67 combretastatin A4 phosphate CA4P 67 dependent kinase inhibitor 67 mertansine 67 Letairis ambrisentan 67 Rotigotine 67 Pimavanserin 67 Phase IIa Clinical Trial 67 Gemcitabine 67 PD LID 67 Pruvel TM 67 small molecule defensin 67 receptor partial agonist 67 NS#/#A protease 67 HCV RNA polymerase 67 idarubicin 67 long acting muscarinic 67 ganetespib 67 CA4P 67 Bosutinib 67 dopamine partial agonist 67 Phase III Pivotal 67 Symadex 67 gemcitabine Gemzar 67 Factor Receptor 67 Pazopanib 67 Plicera 67 phase IIb clinical 67 myelodysplastic myeloproliferative diseases 67 Peginterferon 67 Fludara ® 67 Dalbavancin 67 Natalizumab 67 Genasense ® 67 IgG1 monoclonal antibody 67 Vidaza R 67 targeted antifolate 67 Cyclooxygenase Inhibiting Nitric Oxide 67 OXi# 67 HCV protease inhibitor 67 HMG CoA reductase inhibitors 67 Novel Mechanism 67 Cetrorelix 67 leading oral taxane 67 Saxagliptin 67 Initiates Clinical 67 immunomodulatory 67 selective inhibitor 67 Kinase Inhibitors 67 VEGFR2 inhibitor 67 vinorelbine tartrate 67 cyclophosphamide methotrexate 67 Randomized Double blind 67 MKC# MT 67 Mipomersen 67 Trodusquemine MSI 66 HGS ETR1 mapatumumab 66 modulator SERM 66 Receptor Agonist 66 Bicifadine 66 Systemic Sclerosis 66 5 fluorouracil leucovorin 66 Histone Deacetylase 66 Taxanes 66 entinostat 66 Lymphocytic 66 immunomodulator 66 SYN# 66 Presents Preclinical 66 Mitoxantrone 66 Lenocta 66 metastatic renal cell carcinoma 66 investigational humanized monoclonal antibody 66 HuMax CD4 66 recurrent glioblastoma multiforme 66 multi kinase inhibitor 66 Novel Antibiotic 66 humanized monoclonal 66 Antiviral Activity 66 Phase 2a Trial 66 Janus kinase 66 potentially hepatotoxic 66 nucleoside 66 TO AVOID PREGNANCY WHILE 66 Castration Resistant Prostate Cancer 66 Vinorelbine 66 vorinostat 66 Atripla combines 66 xanthine oxidase inhibitor 66 Phase III Clinical Trial 66 Zalypsis 66 Myelodysplastic Syndrome MDS 66 refractory cutaneous T 66 Adalimumab 66 Fc fusion protein 66 FOLFOX6 66 CCX# 66 imatinib resistant 66 IL# PE#QQR 66 MNTX 66 intranasal formulation 66 Cytarabine 66 Mg Usa 66 IMC A# 66 5 HT3 antagonist 66 TELINTRA R 66 somatostatin analog 66 ANYARA 66 PGL# 66 R sorafenib tablets 66 Exelixis XL# 66 estramustine 66 ELACYT 66 Boceprevir 66 Laquinimod 66 plus DOXIL 66 beta 1a 66 ZOLINZA 66 Relapsed 66 Initiates Phase III 66 interferon alfa 66 Tasimelteon 66 Phase 2b Study 66 Diabetic Nephropathy 66 ADP receptor antagonist 66 Cytotoxic 66 Chronic Myeloid Leukemia 66 Adjunctive Therapy 66 proteasome inhibitors 66 cytostatic 66 Raltegravir 66 Onyx Pharmaceuticals Announces 66 metastatic castration resistant 66 Receives Orphan Drug Designation 66 Unresectable 66 pegylated 66 trabectedin 66 TLR9 agonist 66 Sym# 66 R lenalidomide 66 Sudhir Agrawal D.Phil 66 metastatic malignant 66 PEGylated interferon 66 Immunotherapeutic 66 Immunomodulatory 66 Initiates Phase II 66 Onco TCS 66 Receptor Antagonists 66 BXT # 66 antibody MAb 66 HuLuc# 66 cutaneous T cell 66 monoclonal antibody conjugated 66 EGFR tyrosine kinase inhibitor 66 oral dual endothelin 66 compound PMX # 66 Atiprimod 66 Anticancer Compound 66 metformin sulfonylurea 66 selective agonist 66 SAR# [004] 66 irreversible inhibitor 66 Pooled Analysis 66 DermaVir Patch 66 superficial bladder cancer 66 Lupus Nephritis 66 non porcine pancreatic 66 interferon gamma 1b 66 Chronic Lymphocytic Leukemia CLL 66 ixabepilone 66 dacarbazine DTIC 66 xenograft models 66 voreloxin 66 PSN# [001] 66 Naive Patients 66 Ambrisentan 66 acyclovir Lauriad R 66 Monoclonal Antibody 66 MTP inhibitor 66 Receptor Antagonist 66 Preclinical Models 66 Prodrug 66 Adjuvant Treatment 66 Omnitarg 66 JAK2 inhibitor 66 Study Evaluating 66 EOquin TM phase 66 Treatment Naïve 66 Phase III Trial 66 Akt inhibitor 66 zidovudine AZT 66 BAL# [001] 66 Pirfenidone 66 ® bortezomib 66 anti leukemic 66 HuMax EGFr 66 essential thrombocythemia 66 KRN# 66 Exemestane 66 NXL# 66 anticancer agent 66 methylnaltrexone bromide 66 Initiates Clinical Trial 66 HCV NS5B polymerase 66 anionic backbone 66 OncoVEX GM CSF 66 Complicated Skin 66 Telbivudine 66 Enzastaurin 66 demonstrated antitumor activity 66 Degarelix 66 Cardiotoxicity 66 candidates Azedra TM 66 selective androgen receptor modulator 66 HCD# [002] 66 Investigational Oral 66 BLP# Liposome Vaccine 66 MT# MEDI 66 Epothilones 66 Newly Diagnosed 66 AVONEX ® 66 forodesine hydrochloride 66 NR2B selective 66 SERMs 66 apoptosis proteins 66 Protein Kinase C 66 Vorinostat 66 histone deacetylase inhibitor 66 Racivir 66 Receives Orphan Drug 66 ALS #-# 66 Cloretazine R VNP#M 66 estrogen receptor antagonist 66 ALN PCS 66 Calcitonin 66 Soft Tissue Sarcoma 66 Pegasys ® 66 HGS# 66 Fluorouracil 66 Imprime PGG 65 Dose Escalation 65 Zolinza 65 including eniluracil ADH 65 Tigecycline 65 Palonosetron 65 FDA APPROVES 65 Velcade bortezomib 65 PXD# 65 huN# DM1 65 dacarbazine 65 Recombinant Human 65 dextromethorphan quinidine 65 cyclin dependent kinase inhibitor 65 oxaliplatin Eloxatin 65 Tiotropium 65 Azedra 65 Anidulafungin 65 Interferon Beta 65 Imatinib mesylate 65 Anthracyclines 65 pertuzumab 65 PEGylated 65 HCV NS3 protease 65 Relapsed Refractory Multiple Myeloma 65 biologic therapy 65 PrevOnco 65 Phase 2a Study 65 BMS # 65 Files IND 65 compound perifosine 65 gemcitabine cisplatin 65 Tarceva TM 65 CDK cyclin dependent 65 Signaling Pathway 65 Cisplatin 65 Microplasmin 65 Bucindolol 65 6 sulfatase 65 small molecule tyrosine 65 novel DACH platinum 65 candidate deforolimus 65 N methyl 65 YONDELIS R 65 Bazedoxifene 65 First Patient Dosed 65 nitric oxide donating prostaglandin 65 GSK# [001] 65 IMiD 65 Chronic Hepatitis C 65 EndoTAG TM -1 65 relapsed refractory multiple myeloma 65 N acetylgalactosamine 6 65 Peginterferon Alfa 2a 65 PDX pralatrexate 65 Pradefovir 65 Onconase 65 Cariprazine 65 DU #b 65 systemic fungal infections 65 Cathepsin S 65 mda 7 65 Melphalan 65 administered subcutaneously 65 Vaprisol 65 reverse transcriptase inhibitors 65 LY# [003] 65 EGFr 65 FOLFOX6 chemotherapy regimen 65 oral anti arrhythmic 65 pegylated interferons 65 oral nucleoside analogue 65 demethylating agent 65 Initiates Enrollment 65 Liposomal 65 metastatic neuroendocrine tumors 65 melphalan prednisone 65 Darusentan 65 refractory indolent non 65 intravesical instillation 65 ® lenalidomide 65 LymphoStat B TM 65 huC# DM4 65 delivers fluocinolone acetonide FA 65 Acute Myeloid Leukemia AML 65 humanized monoclonal antibody 65 tiapamil 65 ZYBRESTAT 65 Campath ® 65 EGFR TKI 65 R Saizen R 65 inflammatory PDE 65 CYP#A# isoenzyme 65 orally dosed 65 Previously Untreated 65 Crohn disease CD 65 Belinostat 65 JAK inhibitor 65 complement inhibitor eculizumab 65 endothelin receptor 65 Small Molecule 65 cancer mCRC 65 oral Factor Xa 65 bendamustine 65 Lenocta TM 65 IMiDs 65 Phase #/#a trial 65 L Annamycin 65 Gleevec imatinib mesylate 65 2A receptor agonist 65 CB2 selective receptor agonist 65 KSP inhibitor 65 HER1 65 Aurora kinase 65 liposome encapsulated 65 hyaluronidase enzyme 65 Etoposide 65 PEGylated interferon beta 1a 65 agent VDA 65 Paclitaxel Carboplatin 65 Metastatic Renal Cell Carcinoma 65 interferon IFN 65 R roscovitine 65 platinum chemotherapeutic 65 KNS # 65 JAK2 enzyme 65 Familial Adenomatous Polyposis FAP 65 calcineurin inhibitors 65 Androgen Receptor 65 Cloretazine R 65 BCG refractory carcinoma 65 GALNS N acetylgalactosamine 65 Crizotinib 65 seliciclib 65 stable nucleic acid 65 Daptomycin 65 BARACLUDE R 65 polyglutamate 65 Perifosine KRX 65 benzimidazole 65 depsipeptide 65 diarrhea predominant irritable 65 low dose cytarabine 65 nucleotide analogue 65 treat chronic sinusitis 65 HMG CoA reductase inhibitor 65 Tiuxetan 65 systemic juvenile idiopathic 65 Double Blind Placebo 65 pegylated liposomal doxorubicin 65 oral beclomethasone dipropionate 65 gefitinib Iressa 65 selective A2A adenosine receptor 65 Copegus ribavirin 65 Vandetanib 65 alkylating 65 ALK inhibitor 65 Panzem NCD 65 immunomodulatory therapy 65 Aviptadil 65 Oral Anticoagulant 65 IRX 2 65 HCV protease inhibitors 65 alpha TNFa 65 rxRNA 65 ocular formulation 65 BRIM2 65 glycoprotein GP IIb IIIa 65 FOLFOX chemotherapy 65 Estrogen Receptor 65 Azacitidine 65 Squalamine 65 hypereosinophilic syndrome 65 K ras mutations 65 mesylate 65 lamivudine 3TC 65 Tesamorelin 65 tyrosine kinase inhibitor TKI 65 Taxane 65 MVA BN R 65 selective estrogen receptor 65 reverse transcriptase inhibitor 65 Chronic Lymphocytic Leukemia 65 Anti TNF 65 metastatic colorectal 65 Sodium oxybate 65 CRTH2 65 relapsing multiple sclerosis 65 R bortezomib 65 novel tubulin binding 65 small molecule glucokinase 65 Omacetaxine mepesuccinate 65 therapeutically inactive prodrug 65 EOquin 65 Ocrelizumab 65 PRN FDA Approves 65 Pharmacokinetic Study 65 Anti VEGF 65 Successfully Completes Phase 65 Etanercept 65 HCV Protease Inhibitor 65 Initiates Phase 2b 65 Advanced Melanoma 65 RAV# 65 TRC# 65 epothilone 65 Ostabolin C TM 65 AP# [003] 65 Leukine ® 65 ZEVALIN ® 65 irinotecan containing 65 Tipranavir 65 denileukin diftitox 65 systemic antifungal 65 Parathyroid Hormone 65 DP VPA 65 tumors GIST 65 antimetabolite 65 Zevalin R Ibritumomab 65 novel histone deacetylase 65 Genasense ® oblimersen 65 Newly Diagnosed Multiple Myeloma 65 Therapeutic Vaccine 65 R#/MEM # 65 Atypical Hemolytic Uremic Syndrome 65 Ranolazine 65 MAP# 65 advanced carcinoid 65 CR# vcMMAE 65 Ovitrelle R Serostim 65 acute leukemias 65 cortisol synthesis 65 Naproxcinod 65 Cyclooxygenase 2 65 Factor VIIa 65 Systemic Delivery 65 neutropenia dehydration dyspnea 65 lintuzumab SGN 65 OMP #R# 65 interferon beta 1a infertility 65 refractory AML 65 soluble tumor necrosis 65 Lacosamide 65 RhuDex TM 65 Chronic HCV 65 R roscovitine CDK cyclin 65 TTF Therapy 65 transcriptase inhibitor NNRTI 65 DNA methyltransferase inhibitors 65 tezampanel 65 ritonavir boosted 65 biologic DMARD 65 Everolimus 65 metastatic hormone refractory 65 CCR5 antagonist 65 adriamycin 65 FOLFIRI 65 Apoptone 65 NS5b 65 hypoxia activated prodrug 65 Rigel R# 65 axitinib 65 Vitro Activity 65 Interferon alpha 65 corticosteroid dexamethasone 64 Malignant Glioma 64 5 HT2A inverse 64 plus prednisone prednisolone 64 Cyclophosphamide 64 topically administered 64 Copegus ® 64 potent triglyceride lowering 64 5 HT6 64 CYT# vascular disrupting 64 Interferon alfa 64 SinuNase TM 64 Systemic lupus erythematosus SLE 64 Myelodysplastic Syndromes 64 Pegylated Liposomal Doxorubicin 64 basal bolus regimen 64 endothelin receptor antagonists 64 triggers apoptosis programmed 64 Plecanatide 64 CD4 monoclonal antibody 64 DDP# 64 GRNOPC1 contains 64 erlotinib Tarceva R 64 Paraplatin ® 64 stage IIIB 64 Tolvaptan 64 APTIVUS r 64 recurrent metastatic ovarian cancer 64 OvaRex R 64 CYP#A# substrate 64 II Clinical Trial 64 hypoxia inducible factor 64 Bronchiectasis 64 agonistic human 64 compound INCB# 64 rhIGFBP 3 64 Angiotensin Converting Enzyme 64 peptibody 64 nucleoside analogs 64 dihydrofolate reductase 64 Lixisenatide 64 SCCHN 64 GMX# 64 XmAb# 64 ELND-#/AZD-# 64 glioblastoma multiforme GBM 64 Achieves Primary Endpoint 64 directed radiotherapeutic antibody 64 selectively inhibited 64 Antitumor activity 64 docetaxel chemotherapy 64 Galantamine 64 generation antisense inhibitor 64 diabetic neuropathic pain 64 peptide conjugated 64 PDE4 64 agonist LABA 64 GV# [001] 64 ISTODAX ® 64 immune modulatory 64 Is Well Tolerated 64 paclitaxel Taxol R 64 epithelial tumors 64 trial evaluating PRX# 64 thetreatment 64 Aztreonam lysine 64 registrational trial 64 gastrin analogue TT 64 Pulmonary Arterial Hypertension 64 alpha interferons 64 Begins Dosing 64 ProLindac TM 64 VNP#M 64 Mg Uk 64 Dendritic Cells 64 XL# XL# XL# 64 MKC# 64 cidofovir 64 novel orally bioavailable 64 Potent Inhibitor 64 PROSTASCINT R 64 oncolytic vaccine 64 drug pipeline TAFA# 64 Granted Orphan Drug 64 Arimoclomol 64 TYKERB 64 RhuDex R 64 INCB# [003] 64 IMPDH inhibitor 64 Octreotide 64 Quinamed R 64 Selective Inhibitor 64 subcutaneously administered 64 Phase III Trials 64 Tocilizumab 64 Ceflatonin 64 Sphingomab 64 MT#/MEDI-# 64 Cethromycin 64 IFN α